Entyvio (Vedolizumab) belongs to the class of medications called biologic response modifiers. It is used for the treatment of adults with moderately to severely active Ulcerative Colitis or Crohn's Disease when there has been a poor response to other treatments, or these treatments are no longer effective or have unacceptable side effects.
Available form
Injectable, Powder, Injectable
Dosage
Manufacturer
Takeda
We won't bore you with the details, but Health Canada requires you to sign in.
By proceeding you agree to our Terms of Use & Privacy Policy
The usual adult dose of Entyvio (Vedolizumab) is 300 mg given by intravenous (into a vein) injection over 30 minutes. The first three doses are given with the first on week 0, then 2 weeks after the first dose, then 6 weeks after the first dose. After the first 3 doses, further treatments are given every 8 weeks.
All treatments are given in a hospital or similar setting with access to sterile equipment for preparation of the medication and facilities to treat medical emergencies, such as infusion reactions.
Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are taking the medication without consulting your doctor.
It is important Entyvio (Vedolizumab) be given exactly as recommended by your doctor. If you miss an appointment to receive Entyvio (Vedolizumab), contact your doctor as soon as possible to reschedule your appointment.
Entyvio (Vedolizumab) must be refrigerated at 2°C to 8°C (do not freeze), protected from light, and kept out of the reach of children.
Do not dispose of medications in wastewater (e.g. down the sink or in the toilet) or in household garbage. Ask your pharmacist how to dispose of medications that are no longer needed or have expired.
Many medications can cause side effects. A side effect is an unwanted response to a medication when it is taken in normal doses. Side effects can be mild or severe, temporary or permanent.
The side effects listed below are not experienced by everyone who takes Entyvio (Vedolizumab). If you are concerned about side effects, discuss the risks and benefits of Entyvio (Vedolizumab) with your doctor.
The following side effects have been reported by at least 1% of people taking Entyvio (Vedolizumab). Many of these side effects can be managed, and some may go away on their own over time.
Contact your doctor if you experience these side effects and they are severe or bothersome. Your pharmacist may be able to advise you on managing side effects.
Although most of the side effects listed below don't happen very often, they could lead to serious problems if you do not seek medical attention.
Check with your doctor as soon as possible if any of the following side effects occur:
Stop taking the medication and seek immediate medical attention if any of the following occur:
Some people may experience side effects other than those listed. Check with your doctor if you notice any symptom that worries you while you are taking Entyvio (Vedolizumab).
Each single-use vial containing a white-to-off-white cake contains 300 mg of Entyvio (Vedolizumab). Nonmedicinal ingredients: L-histidine, L-histidine monohydrochloride, L-arginine hydrochloride, sucrose, and polysorbate 80.
Do not take Entyvio (Vedolizumab) if you:
There may be an interaction between Entyvio (Vedolizumab) and any of the following:
If you are taking any of these medications, speak with your doctor or pharmacist. Depending on your specific circumstances, your doctor may want you to:
An interaction between two medications does not always mean that you must stop taking one of them. Speak to your doctor about how any drug interactions are being managed or should be managed.
Medications other than those listed above may interact with Entyvio (Vedolizumab). Tell your doctor or prescriber about all prescription, over-the-counter (non-prescription), and herbal medications you are taking. Also tell them about any supplements you take. Since caffeine, alcohol, the Nicotine from cigarettes, or street drugs can affect the action of many medications, you should let your prescriber know if you use them.
Before you begin using a medication, be sure to inform your doctor of any medical conditions or Allergies you may have, any medications you are taking, whether you are pregnant or breast-feeding, and any other significant facts about your health. These factors may affect how you should use Entyvio (Vedolizumab).
Allergic reactions: In rare cases, some people may develop a severe allergic reaction to Entyvio (Vedolizumab). These reactions may not occur with the first infusion of the medication, and may happen with future doses of Entyvio (Vedolizumab). Your health care provider will monitor you while you are receiving Entyvio (Vedolizumab) by infusion. Signs of an allergic reaction include a severe rash, Hives, swollen face or throat, difficulty breathing, lightheadedness, or dizziness. If any of these occur, contact your doctor immediately.
Infections: Entyvio (Vedolizumab) may increase the risk of developing an infection, including serious infections such as sepsis, pneumonia, and tuberculosis. Before starting Entyvio (Vedolizumab) treatment, your doctor may test to see if you have tuberculosis. If you notice signs of an infection such as fever, chills, pain, swelling, coughing, or pus, contact your doctor as soon as possible. Entyvio (Vedolizumab) should also not be started while you have an active infection.
Liver function: Entyvio (Vedolizumab) can cause decreased liver function. If you have liver problems, discuss with your doctor how Entyvio (Vedolizumab) may affect your medical condition, how your medical condition may affect the dosing and effectiveness of Entyvio (Vedolizumab), and whether any special monitoring is needed. If you experience symptoms of liver problems such as fatigue, feeling unwell, loss of appetite, nausea, yellowing of the skin or whites of the eyes, dark urine, pale stools, abdominal pain or swelling, and itchy skin, contact your doctor immediately.
Progressive multifocal leukoencephalopathy (PML): Although there have not been reports of PML after using Entyvio (Vedolizumab), it has been reported with other medications in the same family. PML is a rare disorder that causes nerve damage in the brain. If you experience memory loss, vision loss, trouble thinking, or difficulty walking, contact your doctor immediately.
Vaccines: Live vaccines (e.g., BCG, yellow fever) are not recommended for people taking Entyvio (Vedolizumab). Talk to your doctor if you need any vaccinations while taking Entyvio (Vedolizumab).
Pregnancy: Entyvio (Vedolizumab) should not be used during pregnancy. If you are of childbearing age, effective birth control should be used while you are being treated with Entyvio (Vedolizumab) and for at least 18 weeks after your final treatment. If you become pregnant while taking Entyvio (Vedolizumab), contact your doctor immediately.
Breast-feeding: Entyvio (Vedolizumab) passes into breast milk. If you are a breast-feeding mother and are taking Entyvio (Vedolizumab), it may affect your baby. Talk to your doctor about whether you should continue breast-feeding.
Children: The safety and effectiveness of using Entyvio (Vedolizumab) have not been established for children.
It’s like having us in your pocket, putting you first in every interaction.
Your medication is delivered to you at no added cost.
Call, text, email—whatever works for you. We’re humans, ready to help.
Discreet with real-time updates. Go about your day, your meds are on the way.
Your region
,
Pocketpills is licensed by
Accreditation No
#
Pharmacy Manager
2025 Pocketpills
Pocketpills is not a pharmacy
or a drug manufacturer